3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 9, 2009, Pages 2464-2467

  Vu, An T ^a   Cohn, Stephen T ^a   Terefenko, Eugene A ^a   Moore, William J ^a   Zhang, Puwen ^a   Mahaney, Paige E ^a   Trybulski, Eugene J ^a   Goljer, Igor ^a   Dooley, Rebecca ^a   Bray, Jenifer A ^a   Johnston, Grace H ^a   Leiter, Jennifer ^a   Deecher, Darlene C ^a  

^a PFIZER INC   (United States)

Author keywords

3 (Arylamino) 3 phenylpropan 2 olamines; Monoamine reuptake inhibitors; Norepinephrine reuptake inhibitors; NRI; Serotonin and norepinephrine reuptake inhibitors; Serotonin reuptake inhibitor; SNRI; SRI

Indexed keywords

ATOMOXETINE; DOPAMINE TRANSPORTER; DULOXETINE; FLUOXETINE; MAZINDOL; NORADRENALIN UPTAKE INHIBITOR; PROPANOLAMINE DERIVATIVE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR;

AMINE TRANSPORT; ANIMAL CELL; ARTICLE; BINDING AFFINITY; DRUG SCREENING; DRUG SYNTHESIS; INHIBITION KINETICS; NONHUMAN; NORADRENALIN UPTAKE; SEROTONIN UPTAKE; STATISTICAL SIGNIFICANCE;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DOGS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DRUG DESIGN; HUMANS; INHIBITORY CONCENTRATION 50; LIGANDS; MODELS, CHEMICAL; NOREPINEPHRINE; PROPANOLAMINES; SEROTONIN UPTAKE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 64249098647     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.03.054     Document Type: Article

References (31)

1. Walter M.W. Drug. Dev. Res. 65 (2005) 97-118
2. Bymaster F.P., McNamara R.K., and Tran P.V. Exp. Opin. Invest. Drugs 12 (2003) 531-543
3. For a recent review on norepinephrine reuptake inhibitors, see:. Babu R.P.K., and Maiti S.N. Heterocycles 69 (2006) 539-567
4. Christman A.K., Fermo D.J., and Markowitz J.S. Pharmacotherapy 24 (2004) 1020-1026
5. Hajos M., Fleishaker J.C., Filipiak-Reisner J.K., Brown M.T., and Wong E.H.F. CNS Drug Rev. 10 (2004) 23-44
6. Krell H.V., Leuchter A.F., Cook I.A., and Abrams M. Psychosomatics 46 (2005) 379-384
7. Berigan T. Can. J. Psychiatry 49 (2004) 499-500
8. Tran P.V., Bymaster F.P., McNamara R.K., and Potter W.Z. J. Clin. Psychopharmacol. 23 (2003) 78-86
9. Collins S.D., and Chessell I.P. Exp. Opin. Emerg. Drugs 10 (2005) 95-108
10. McCormack P.L., and Keating G.M. Drugs 64 (2004) 2567-2573
11. Zhang P., Terefenko E.A., McComas C.C., Mahaney P., Vu A., Trybulski E., Koury E., Johnston G., Bray J., and Deecher D. Bioorg. Med. Chem. Lett. 18 (2008) 6067-6070
12. McComas C.C., Vu A.T., Mahaney P.E., Cohn S.T., Fensome A., Marella M.A., Nogel L., Trybulski E.J., Ye F., Zhang P., Alfinito P., Bray J.A., Johnston G.H., Koury E.J., and Deecher D.C. Bioorg. Med. Chem. Lett. 18 (2008) 4929-4931
13. Mahaney P.E., Gavrin L.K., Trybulski E.J., Stack G.P., Vu A.T., Cohn S.T., Ye F., Belardi J.K., Santilli A.A., Sabatucci J.P., Leiter J., Johnston G.H., Bray J.A., Burroughs K.D., Cosmi S.A., Leventhal L., Koury E.J., Zhang Y., Mugford C.A., Ho D.M., Rosenzweig-Lipson S.J., Platt B., Smith V.A., and Deecher D.C. J. Med. Chem. 51 (2008) 4038-4049
14. Mahaney P.E., Vu A.T., McComas C.C., Zhang P., Nogle L.M., Watts W.L., Sarkahian A., Leventhal L., Sullivan N.R., Uveges A.J., and Trybulski E.J. Bioorg. Med. Chem. 14 (2006) 8455-8466
15. Xu W., Gray D.L., Glase S.A., and Barta N.S. Bioorg. Med. Chem. Lett. 18 (2008) 5550-5553
16. Hudson S., Kiankarimi M., Eccles W., Mostofi Y.S., Genicot M.J., Dwight W., Fleck B.A., Gogas K., and Wade W.S. Bioorg. Med. Chem. Lett. 18 (2008) 4495-4498
17. Hudson S., Kiankarimi M., Eccles W., Dwight W., Mostofi Y.S., Genicot M.J., Fleck B.A., Gogas K., Aparicio A., Wang H., Wen J., and Wade W.S. Bioorg. Med. Chem. Lett. 18 (2008) 4491-4494
18. Wu D., Pontillo J., Ching B., Hudson S., Gao Y., Fleck B.A., Gogas K., and Wade W.S. Bioorg. Med. Chem. Lett. 18 (2008) 4224-4227
19. Cases-Thomas M.J., Masters J.J., Walter M.W., Campbell G., Haughton L., Gallagher P.T., Dobson D.R., Mancuso V., Bonnier B., Giard T., Defrance T., Vanmarsenille M., Ledgard A., White C., Ouwerkerk-Mahadevan S., Brunelle F.J., Dezutter N.A., Herbots C.A., Lienard J.Y., Findlay J., Hayhurst L., Boot J., Thompson L.K., and Hemrick-Luecke S. Bioorg. Med. Chem. Lett. 16 (2006) 2022-2025
20. Beadle C.D., Boot J., Camp N.P., Dezutter N., Findlay J., Hayhurst L., Masters J.J., Penariol R., and Walter M.W. Bioorg. Med. Chem. Lett. 15 (2005) 4432-4437
21. Wakenhut F., Fish P.V., Fray M.J., Gurrell I., Mills J.E., Stobie A., and Whitlock G.A. Bioorg. Med. Chem. Lett. 18 (2008) 4308-4311
22. Whitlock G.A., Fish P.V., Fray M.J., Stobie A., and Wakenhut F. Bioorg. Med. Chem. Lett. 18 (2008) 2896-2899
23. Fish P.V., Deur C., Gan X., Greene K., Hoople D., Mackenny M., Para K.S., Reeves K., Ryckmans T., Stiff C., Stobie A., Wakenhut F., and Whitlock G.A. Bioorg. Med. Chem. Lett. 18 (2008) 2562-2566
24. Whitlock G.A., Blagg J., and Fish P.V. Bioorg. Med. Chem. Lett. 18 (2008) 596-599
25. Introduction of a β-hydroxyl group into the aryloxypropanamine framework was described previously by Melloni and co-workers. See Ref. 13.
26. Melloni P., Carniel G., Torre A.D., Bonsignori A., Buonamici M., Pozzi O., Ricciardi S., and Rossi A.C. Eur. J. Med. Chem. 19 (1984) 235-242
27. For detailed synthetic procedures, see: US 2008085938 A1.
28. Yang D., Wong M.-K., and Yip Y.-C. J. Org. Chem. 60 (1995) 3887-3889
29. 13C gHSQC, gHMBC and 1,1-ADEQUATE. {A figure is presented}
30. Since the in vitro data in Table 1 are for racemic compounds, it is possible that the contributing effects from each enantiomer may be unequal. See Ref. 11c.
31. Hitchcock S.A., and Pennington L.D. J. Med. Chem. 49 (2006) 7559-7583